The calcitonin gene-related peptide (CGRP) monoclonal antibodies (MABs) erenumab (Aimovig®), fremanezumab (Ajovy®) and galcanezumab (Emgality®) are available under the High Tech Arrangement. A Managed Access Protocol is in place for the CGRP MABs. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of erenumab, fremanezumab or galcanezumab under the High Tech Arrangement.
The prescribing of erenumab (Aimovig®), fremanezumab (Ajovy®) and galcanezumab (Emgality®) under the High Tech Arrangement is confined to consultant neurologists who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme.
The clinician must submit an online application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
A copy of the HSE-Managed Access Protocol for CGRP MABs can be found in the Related Files section below.